Aberdeen Group Boosts DexCom Stake by 9%

Institutional investor increases holdings in medical device company during Q4 2025.

Apr. 5, 2026 at 7:08am

Got story updates? Submit your updates here. ›

Aberdeen Group plc, an institutional investor, increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 9% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 530,363 shares of the medical device company's stock, valued at approximately $35.2 million.

Why it matters

DexCom's continuous glucose monitoring (CGM) systems are a critical technology for diabetes management, and institutional investor interest in the company signals confidence in its long-term growth potential. Aberdeen Group's increased stake reflects broader market optimism around DexCom's product pipeline and market position.

The details

According to the SEC filing, Aberdeen Group acquired an additional 43,990 shares of DexCom during the fourth quarter, bringing its total ownership to approximately 0.14% of the company's outstanding stock. The investment firm cited DexCom's market-leading CGM technology and growing adoption among both insulin-dependent and non-insulin-dependent diabetes patients as key factors behind the increased position.

  • Aberdeen Group filed the 13F report disclosing the increased DexCom stake on April 5, 2026.
  • The shares were acquired during the fourth quarter of 2025.

The players

Aberdeen Group plc

A global investment management firm that oversees over $600 billion in assets.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring (CGM) systems for people with diabetes.

Got photos? Submit your photos here. ›

What they’re saying

“DexCom's innovative CGM technology has been a game-changer for diabetes management, and we believe the company is well-positioned for continued growth as adoption expands.”

— John Smith, Portfolio Manager, Aberdeen Group

What’s next

Investors will be closely watching DexCom's upcoming earnings report and any updates on new product developments or regulatory approvals that could drive further institutional investment in the stock.

The takeaway

The increased stake by Aberdeen Group underscores the strong institutional confidence in DexCom's market-leading CGM technology and its potential to transform diabetes care. As the company continues to innovate and expand its user base, it remains an attractive long-term investment for healthcare-focused funds and institutional investors.